miR‐146a‐5p and miR-193a-5p Synergistically Inhibited the Proliferation of Human Colorectal Cancer Cells (HT-29 cell line) through ERK Signaling Pathway

Advanced Pharmaceutical Bulletin - Tập 11 Số 4 - Trang 755-764 - 2020
Saeed Noorolyai1, Elham Baghbani1,2, Dariush Shanehbandi1, Vahid Khaze1, Amir Baghbanzadeh1, Behzad Mansoori1, Khalil Hajiasgharzadeh1,2, Ahad Mokhtarzadeh1, Behzad Baradaran3
1Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
3Pharmaceutical Analysis Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Tóm tắt

Purpose: The expression of miR-146a-5p and miR-193a-5p in colorectal cancer (CRC) is associated with cancer development, metastasis, and reduced survival rate of the tumor-suffered subjects. This examination aimed to assess the impact of these microRNAs (miRNAs) in CRC and their mechanisms in the proliferation and migration of cancer cells. Methods: miR-146a-5p and -193a-5p were transfected into the HT-29 cell line and assessed their impact on metastasis-related genes. The synergistic effects of these miRNAs on migration were evaluated by wound healing approach. To assess the influence of these miRNAs on the proliferation of and apoptosis of cells, the MTT test, annexin V staining test, and DAPI staining test were done. Then, the protein expression of extracellular-signal-regulated kinase (ERK) and phosphorylated ERK (p-ERK) were investigated. Results: miR-146a-5p and-193a-5p could inhibit the CRC cells proliferation, and could synergistically induce apoptosis in CRC cells, and also repressed cell migration, and could reduce p-ERK expression. Conclusion: miR-146a-5p and-193a-5p have an important role in cell viability and proliferation via ERK signaling pathway. Thus, the simultaneous use of these miRNAs may be suggested as a probable therapeutic strategy in this cancer therapy.

Từ khóa


Tài liệu tham khảo

10.1177/1758834016646734

10.1016/j.canlet.2017.11.008

10.3322/caac.21492

10.4161/rna.24604

10.1002/jcp.25801

10.4103/2229-3485.179431

10.3390/cancers7030842

10.1016/j.bbrc.2016.10.054

10.1002/jcb.28164

10.1053/j.gastro.2009.03.041

10.3748/wjg.v24.i39.4428

10.5681/bi.2012.019

10.5681/apb.2014.032

10.1016/j.molonc.2012.09.006

10.1101/gad.1184704

10.1073/pnas.0510565103

10.18632/oncotarget.15158

10.3748/wjg.v20.i34.12241

10.1371/journal.pone.0165912

10.1002/jcp.26891

10.1038/onc.2013.122

10.1038/nrc2664

10.1002/ijc.24604

10.1016/j.biopha.2016.11.124

10.1158/0008-5472.can-08-3559

10.1200/JCO.2016.34.15_suppl.e15034

10.1159/000335790

10.1038/srep42226

10.3892/ol.2017.6063

Zeng C, 2014, [Expression of miR-146a in colon cancer and its significance], Nan Fang Yi Ke Da Xue Xue Bao, 34, 396